@ElGlobalNet<\/p>\n
Jimenez, who was already acting president following Viechbacher's resignation, has his term extended until June 2017, although the decision will need to be approved at the next EFPIA general meeting in June 2015.<\/p>\n Upon hearing the decision, the head of Novartis acknowledged that he is taking on this role at a very important stage for the pharmaceutical industry, where the challenge is to put health and life sciences at the center of the European agenda. To do this, said the entrepreneurs' managing director, Richard Bergstr\u00f6m, Jimenez's experience will be essential.<\/p>","protected":false},"excerpt":{"rendered":" Eletti anche i vice presidenti che lo accompagneranno, il CEO di Merck, Stefan Oschmann, e il Presidente e CEO di Ipsen, Marc de Garidel. IL GLOBAL \/ BRUXELLES – Mercoled\u00ec 10 Dicembre 2014 @ElGlobalNet Gli imprenditori europei dell’industria farmaceutica innovativa (EFPIA) hanno annunciato la nomina del CEO Novartis, Joe Jimenez, come nuovo presidente. La decisione …<\/p>","protected":false},"author":4,"featured_media":6259,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[50],"class_list":["post-6255","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-farmindustria"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/6255","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=6255"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/6255\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/6259"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=6255"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=6255"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=6255"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}The European Innovative Pharmaceutical Industry Entrepreneurs (EFPIA) have announced the appointment of Novartis CEO, Joe Jimenez<\/a>as the new president. The decision was agreed by the governing bodies of the association on December 9, in a meeting in which the vice presidents who will accompany him were also elected, the CEO of Merck, Stefan Oschmann<\/a>, and the President and CEO of Ipsen, Marc de Garidel<\/a>.<\/p>\n